Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantegazza, Renato, Wolfe, Gil I., Muppidi, Srikanth, Wiendl, Heinz, Fujita, Kenji P., O'Brien, Fanny L., Booth, Heather D.E., Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905790/
https://www.ncbi.nlm.nih.gov/pubmed/33229455
http://dx.doi.org/10.1212/WNL.0000000000011207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905790/
https://www.ncbi.nlm.nih.gov/pubmed/33229455
http://dx.doi.org/10.1212/WNL.0000000000011207

Ejemplares similares